loading page

Persistent Cytomegalovirus Retinitis following Hematopoietic Stem Cell Transplantation Treated with Viral-Specific T Cells
  • +8
  • Raul Montiel-Esparza ,
  • Michalak S,
  • Dinh Le A,
  • Or C,
  • Nguyen QD,
  • Ruby Khoury,
  • Michael Grimley,
  • Alice Bertaina,
  • Klinger E,
  • Ami Shah,
  • Wood E
Raul Montiel-Esparza
Stanford University Department of Pediatrics
Author Profile
Michalak S
Stanford University Department of Ophthalmology
Author Profile
Dinh Le A
Stanford University Department of Ophthalmology
Author Profile
Or C
University of Missouri Kansas City School of Medicine
Author Profile
Nguyen QD
Stanford University Department of Ophthalmology
Author Profile
Ruby Khoury
Cincinnati Children's Hospital Medical Center Division of Bone Marrow Transplantation and Immune Deficiency
Author Profile
Michael Grimley
Cincinnati Children's Hospital Medical Center Division of Bone Marrow Transplantation and Immune Deficiency
Author Profile
Alice Bertaina
Stanford University Department of Pediatrics
Author Profile
Klinger E
Stanford University Department of Pediatrics
Author Profile
Ami Shah
Stanford University Department of Pediatrics

Corresponding Author:ashah5@stanford.edu

Author Profile
Wood E
Stanford University Department of Ophthalmology
Author Profile

Abstract

Cytomegalovirus retinitis (CMVR) following hematopoietic stem cell transplantation (HCT) for a primary immunodeficiency is a rare but highly morbid condition with potential irreversible consequences despite optimal antiviral pharmacotherapy. Viral-specific T cells (VSTs) pose a promising and safe approach eradicating intractable viral disease. We describe the case of a 21-month-old male with Wiskott-Aldrich syndrome (WAS) and CMVR post-HCT with sustained long-term virologic and clinical response after CMV-specific T cell therapy. This case highlights the need to consider VSTs as an adjunct upfront strategy in refractory CMVR and for routine ophthalmologic screening and surveillance in high-risk patients post-HCT.
09 Jan 2023Submitted to Pediatric Blood & Cancer
09 Jan 2023Submission Checks Completed
09 Jan 2023Assigned to Editor
09 Jan 2023Review(s) Completed, Editorial Evaluation Pending
11 Jan 2023Reviewer(s) Assigned
06 Feb 2023Editorial Decision: Revise Minor
06 Apr 20231st Revision Received
06 Apr 2023Submission Checks Completed
06 Apr 2023Assigned to Editor
06 Apr 2023Review(s) Completed, Editorial Evaluation Pending
06 Apr 2023Reviewer(s) Assigned
28 Apr 2023Editorial Decision: Accept